Our Take
Multi-analyte sensor talk is everywhere; what matters is which companies have FDA clearance or realistic timelines, not engineering ambition.
Why it matters
Continuous glucose monitors dominate diabetes management, but adding lactate, ketones, or electrolytes could expand use cases beyond type 1 diabetes into fitness, ketogenic diets, and acute care. The companies leading this race will capture new user segments and higher reimbursement margins.
Do this week
Device makers and digital health partners: map which executives mentioned clinical trials or regulatory submissions in this interview, then contact their regulatory affairs teams to understand real timelines before committing to integration roadmaps.
Three diabetes tech leaders outline multi-analyte sensor roadmaps
Abbott, PercuSense, and Biolinq spoke with MedTech Dive about adding glucose monitoring to simultaneous measurement of other biomarkers such as lactate, ketones, and electrolytes. The executives discussed technical challenges, regulatory pathways, and commercial applications beyond type 1 diabetes management.
Multi-analyte sensors promise broader use cases than single-molecule continuous glucose monitors. Lactate and ketone monitoring appeal to endurance athletes and people following ketogenic diets. Electrolyte tracking could serve acute care settings where dehydration or electrolyte imbalance matters as much as blood sugar. None of the three executives disclosed FDA clearances for multi-analyte versions of their existing products or announced imminent launches.
The real test is regulatory clearance, not feature announcements
Continuous glucose monitors generate recurring revenue through sensor subscriptions and reimbursement. Adding a second or third biomarker to the same device could justify higher pricing and open markets currently closed to single-analyte sensors. Hospitals and sports science programs might adopt multi-analyte sensors where single-analyte CGMs don't fit the workflow.
However, each new biomarker requires separate validation, clinical trial data, and FDA review. The executives' willingness to discuss the roadmap signals competitive pressure and engineering feasibility, but public statements do not guarantee timelines. The company that achieves FDA clearance first for a clinically useful two-analyte sensor wins a narrow window before competitors catch up.
Request clinical data and regulatory timelines before investing in integration
If you are building software, hardware, or clinical workflows around CGM data, ask each vendor whether their multi-analyte announcements rest on published clinical trials, ongoing FDA submissions, or concept-stage engineering. Request specific regulatory timelines and accuracy targets (e.g., mean absolute relative difference or MARD for each analyte). Avoid locking your product roadmap to a feature that may take 3-5 years or never ship. Single-analyte sensors remain the proven baseline; multi-analyte sensors are a hedge, not a certainty.